サルビア・ディビノラム
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/10/16 10:06 UTC 版)
サルビア・ディビノラム（学名Salvia divinorum）は、メキシコ合衆国のシエラマサテカに自生する、シソ科アキギリ属に属する多年草であり、これに含まれる成分サルビノリンAが幻覚作用を有する。この成分の含有は通常のサルビアとは異なる。カタカナに表記の揺れがありディヴィノルム、ディビノルムとも言うが、法令上は最初に示したとおりである。
- ^ Salvia divinorum Tropicos
- ^ “医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第二条第十五項に規定する指定薬物及び同法第七十六条の四に規定する医療等の用途を定める省令”. e-Gov. 2020年1月10日閲覧。
- ^ Valdés, Leander J. III; Díaz, José Luis; Paul, Ara G. (May 1983). "Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M)". Journal of Ethnopharmacology 7 (3): 287–312. doi:10.1016/0378-8741(83)90004-1. PMID 6876852. Retrieved 2007-05-04.
- ^ Giroud, C.; Felber F., Augsburger M. (2000). "Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland". Forensic Science International 112 (2): 143–150. doi:10.1016/S0379-0738(00)00180-8. PMID 10940599.
- ^ a b c Marushia, Robin (June 2003). "Salvia divinorum: The Botany, Ethnobotany, Biochemistry and Future of a Mexican Mint" (PDF). Ethnobotany. Retrieved 2007-05-04.
- ^ Reisfield, A. (1993). The Botany of Salvia divinorum (Labiatae). SIDA 15(3):349-366.
- ^ Valdés III, L.J. et al. (1987). Studies of Salvia divinorum (Lamiaceae), an hallucinogenic mint from the Sierra Mazateca in Oaxaca, Central Mexico. Economic Botany 41: 283-291.
- ^ Weitlaner, R.J. and Hoppe, W. (1964) The Mazatec In: R. Wauchope (Ed.), Handbook of Middle American Indians, Vol. 7, University of Texas Press, Austin, pp. 516-522
- ^ Cortes, J. (1979) La medicine tradicional en la Sierra Mazateca. Actes du XlIIe Congress, Paris, Societe' des Amen'canistes, 6, 349-356.
- ^ Diaz, J.L. (1979) Ethnopharmacology and taxonomy of Mexican psychodysleptic plants. Journal of Psychedelic Drugs 11. 71--101. New York Emboden, W. (1979) Narcotic Plants, Revised edn., Macmillan Publishing Co., pp. 93--95, 190.
- ^ Ott, J. (1996). Salvia divinorum Epling et Jativa Eleusis, n. 4, pp. 31-39.
- ^ Valdes III, L.J., L.J. Diaz, and A.G. Paul. (1983) Ethnopharmacology of ska Maria Pastora (Salvia divinorum Epling & Jativa-M). J. Ethnopharmacol. 7: 287-312.
- ^ Valdés III, L.J. et al. (1987). Studies of Salvia divinorum (Lamiaceae), an hallucinogenic mint from the Sierra Mazateca in Oaxaca, Central Mexico. Economic Botany 41:283-291.
- ^ Valdes III, L.J., L.J. Diaz, and A.G. Paul. (1983) Ethnopharmacology of ska Maria Pastora (Salvia divinorum Epling & Jativa-M). J. Ethnopharmacol. 7: 287-312.
- ^ Valdes III, L.J (2001a) The Early History of Salvia divinorum. The Entheogen Review 10(2):73-75.
- ^ a b Cunningham CW, Rothman RB, Prisinzano TE. 2011. Neuropharmacology of the naturally occurring k-opioid hallucinogen salvinorin A.Pharmacol Rev 63: 316–347
- ^ Gruber JW, Siebert DJ, Der Marderosian AH, Hock RS. 1999. High performance liquid chromatographic quantification of salvinorin A from tissues of Salvia divinorum epling and játiva-m. Phytochem Anal 10: 22–25.
- ^ Tsujikawa K, Kuwayama K, Miyaguchi H, et al. 2008. Determination of salvinorin A and salvinorin B in Salvia divinorum-related products circulated in Japan. Forensic Sci Int 180: 105–109.
- ^ Medana C, Massolino C, Pazzi M, Baiocchi C. 2006. Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/ multistage mass spectrometry. Rapid Commun Mass Spectrom 20: 131–136.
- ^ Wolowich WR, Perkins AM, Cienki JJ. 2006. Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products. Pharmacotherapy 26: 1268–1272.
- ^ a b Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S. 2002. Salvinorin A: a potent naturally occurring nonnitrogenous k opioid selective agonist. Proc Natl Acad Sci U S A 99: 11934–11939.
- ^ a b Hooker JM, Xu Y, SchifferW, Shea C, Carter P, Fowler JS. 2008. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset, short duration of effects in humans. NeuroImage 41: 1044–1050.
- ^ Hooker JM, Patel V, Kothari S, Schiffer WK. 2009. Metabolic changes in the rodent brain after acute administration of salvinorin A. Mol Imaging Biol 11: 137–143.
- ^ Mendelson JE, Coyle JR, Lopez JC, et al. 2011. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebocontrolled trial. Psychopharmacol 214: 933–939.
- ^ a b MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR. 2013. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacol (Berl) 226: 38–92.
- ^ Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE. 2009.Evaluation of the transport, in vitro metabolism and pharmacokinetics of salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 72: 471–477.
- ^ Nozawa M1, Suka Y, Hoshi T, Suzuki T, Hagiwara H.(2008)Total synthesis of the hallucinogenic neoclerodane diterpenoid salvinorin A.Org Lett. 2008 Apr 3;10(7):1365-8. doi: 10.1021/ol800101v. Epub 2008 Mar 1.
- ^ Sałaga M, Polepally PR, Sobczak M, Grzywacz D, Kamysz W, Sibaev A, Storr M, Do Rego JC, Zjawiony JK, Fichna J.(2014)Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.J Pharmacol Exp Ther. 2014 Jul;350(1):69-78. doi: 10.1124/jpet.114.214239.
- ^ Polepally PR1, White K, Vardy E, Roth BL, Ferreira D, Zjawiony JK.(2013)Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.Bioorg Med Chem Lett. 2013 May 15;23(10):2860-2. doi: 10.1016/j.bmcl.2013.03.111. Epub 2013 Apr 4.
- ^ Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ. 2009. Unconditioned behavioral effects of the powerful k-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328: 588–597.
- ^ Nemeth CL, Paine TA, Rittiner JE, et al. 2010. Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology 210: 263–274.
- ^ Braida D, Donzell A, Martucci R, Sala M. 2011. Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in Wistar rats. Int J Toxicol 30: 650–661
- ^ Carlezon WA Jr, Béguin C, DiNieri JA, et al. 2006. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neuro chemistry in rats. J Pharmacol Exp Ther 316: 440–447.
- ^ Grilli M, Neri E, Zappettini S, et al. 2009. Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals. Neuropsychopharmacology 57: 523–530
- ^ Zawilska JB1, Wojcieszak J.(2013)"Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug"Hum. Psychopharmacol Clin Exp 2013; 28: 403–412.
- ^ Kelly BC. 2011. Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs 32: 46–54.
- ^ Casselman I, Heinrich M. 2011. Novel use of Salvia divinorum: unobtrusive observation using YouTube™. J Ethnopharmacol 138: 662–667.
- ^ Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J. 2010. Use patterns and self-reported effects of Salvia divinorum: an Internet-based survey. Drug Alcohol Depend 111: 250–256.
- ^ Hoover V, Marlowe DB, Patapis NS, Festinger DS, Forman RF. 2008. Internet access to Salvia divinorum: implications for policy, prevention,and treatment. J Subst Abuse Treat 35: 22–27.
- ^ Singh S. 2007. Adolescent salvia substance abuse. Addiction 102: 823–824.
- ^ Przekop P, Lee T. 2009. Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 166: 832.
- ^ Travis CR, Ray GA, Marlowe KF. 2012. A report on nausea and vomiting with discontinuation of chronic use of Salvia divinorum. Case Rep Med 2012: 543747.
- ^ Lange JE, Reed MB, Croff JM, Clapp JD. 2008. College student use of Salvia divinorum. Drug Alcohol Depend 94: 263–266.
- ^ Ford JA, Watkins WC, Blumenstein L. 2011. Correlates of Salvia divinorum use in a national sample: findings from the 2009 National Survey on Drug Use and Health. Add Behav 36: 1032–1037.
- ^ Wu L-T, Woody GE, Yang C, Li J-H, Blazer DG. 2011. Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2011: 53–68.
- ^ Currie CL. 2013. Epidemiology of adolescent Salvia divinorum use in Canada. Drug Alcohol Depend 128: 166–170.
- ^ Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J. 2010. Use patterns and self-reported effects of Salvia divinorum: an Internet-based survey. Drug Alcohol Depend 111: 250–256.
- ^ ケージの前方に5つの穴が開いており、その上部にはそれぞれライトがついている。短時間（通常0.5 - 1秒間）ライトがついているうちに正しい穴にラットが鼻先を入れると後方の給餌カゴにエサが入れられる仕組みとなっている。ライトが短時間しかつかないため、常にライトを見ていないと正解できない。そのため注意力の評価が可能となる。またライトがついていないときに鼻先を入れてもえさは出ないため、鼻先を入れたい衝動を抑える必要があることから衝動性も評価可能
[続きの解説]
「サルビア・ディビノラム」の続きの解説一覧
- 1 サルビア・ディビノラムとは
- 2 サルビア・ディビノラムの概要
- 3 欧米諸国における蔓延
- 4 関連項目
- サルビア・ディビノラムのページへのリンク
